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Abstract
Guidelines have recommended single pool Kt/V > 1.2 as the minimum dose for chronic hemodialysis
(HD) patients on thrice weekly HD. The Dialysis Outcomes and Practice Patterns Study (DOPPS) has
shown that “low Kt/V” (<1.2) is more prevalent in Japan than many other countries, though survival
is longer in Japan. We examined trends in low Kt/V, dialysis practices associated with low Kt/V, and
associations between Kt/V and mortality overall and by gender in Japanese dialysis patients. We
analyzed 5784 HD patients from Japan DOPPS (1999–2011), restricted to patients dialyzing for >1
year and receiving thrice weekly dialysis. Logistic regression models estimated the relationships of
patient characteristics with Kt/V. Logistic models also were used to estimate the proportion of low
Kt/V cases attributable to various treatment practices. Multivariable Cox regression was used to
estimate the associations of low Kt/V, blood ﬂow rate (BFR), and treatment time (TT), with all-cause
mortality. From 1999 to 2009, the prevalence of low Kt/V declined in men (37–27%) and women
(15–10%). BFR <200 mL/min, TT <240 minutes, and dialyzate ﬂow rate (DFR) < 500 mL/min were
common (35, 13, and 19% of patients, respectively) and strongly associated with low Kt/V. Fifteen
percent of low Kt/V cases were attributable to BFR <200 and 13% to TT <240, compared to only 3%
for DFR <500. Lower Kt/V was associated with elevated mortality, more so among women (hazard
ratio [HR] = 1.13 per 0.1 lower Kt/V, 95% CI: 1.07–1.20) than among men (HR = 1.06 per 0.1 lower
Kt/V, 95% CI: 1.00–1.12). The relatively large proportion of low Kt/V cases in Japanese facilities may
potentially be reduced 30% by increasing BFR to 200 mL/min and TT to 4 hours thrice weekly in HD
patients. Associations of low Kt/V with elevated mortality suggest that modiﬁcation of these
practices may further improve survival for Japanese HD patients.
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INTRODUCTION
The Japanese hemodialysis (HD) patient population has
displayed considerably longer survival overall than that
seen in most other countries, with annual mortality risks
of 9% to 10% consistently for HD patients in Japan,
compared with annual risks of 12% to 24% in other
countries.1–5 The longer survival on HD for patients in
Japan compared with those in Europe and North America
has also been shown in prior Dialysis Outcomes and Prac-
tice Patterns Study (DOPPS) analyses by Goodkin et al.
adjusting for differences in patient casemix between
regions.6–8
The reasons for the longer survival of HD patients in
Japan vs. other countries are not clearly understood and
likely are due to numerous factors. However, one of the
intriguing aspects of care in Japan is the use of lower blood
flow rates (BFRs), usually 200 mL/min for a typical HD
treatment, compared with BFRs of 300–500 mL/min in
many other countries.1,9,10 This lower BFR may help facili-
tate the attainment and maintenance of the high rate of
∼92% native arteriovenous fistula (AVF) use that has been
described in Japanese HD patients for at least the past 12
years.1,8–10 From the perspective of dialysis session total
solute clearance, the lower mean body size of HD patients
in Japan compared with patients in many other regions
makes it feasible to use a lower BFR, yet provide good
dialysis adequacy. However, dialysis adequacy, as mea-
sured by single pool (sp) Kt/V, varies considerably among
patients in Japan with a substantial fraction of patients
having an spKt/V < 1.2.
In view of these marked differences in dialysis prescrip-
tion and mortality in Japan vs. other countries, we focus
here in Japan to describe to what extent having a low
spKt/V of <1.2 in Japanese HD patients is attributable to
treatment factors such as BFR, HD session length (treat-
ment time [TT]), and other factors. In addition, we
describe the relation of facility-level practices of Kt/V
achievement, BFR and TT with survival as a means to help
understand which levels of these practices are associated
with the best outcomes for HD patients in Japan. The
understandings from Japan may be applicable to other
countries where low Kt/V is still common.
METHODS
Data source
In the present analysis, 5784 patients were included from
Japan DOPPS phases 1–4: 1756 from 61 facilities in phase
1 (1999–2001), 1284 from 56 facilities in phase 2 (2002–
2004), 1431 from 59 facilities in phase 3 (2005–2007),
and 1313 from 58 facilities in phase 4 (2009–2011). The
DOPPS sampling plan and study methods have been
described elsewhere.11,12 Starting with 7779 patients with
measured Kt/V, patients were excluded from this analysis
if they had been on dialysis less than 1 year (n = 1714) to
minimize the effects of residual renal function on the
results. Moreover, patients were excluded if not dialyzing
three times per week (n = 20), had a TT >5 hours (n =
93), had a BFR >550 mL/min (n = 0), were receiving
hemodiafiltration (n = 162), or had missing data on age or
censoring date (n = 6). Facility-level analyses were limited
to facilities with at least eight patients (n = 5752) meeting
the inclusion criteria.
Kt/V at baseline was calculated according to the second-
generation formula of Daugirdas.13 BFR and dialyzate flow
rate (DFR) at baseline were based on prescribed values.
DFR prescription was unavailable in phase 4. Treatment
time at baseline was based on actual TT in phases 2–4.
In phase 1, actual TT was not available, so prescribed TT
was used.
Statistical analysis
Baseline values were reported as percentiles, means, or
percentages. Mean Kt/V was reported by gender and
weight for patients with TT = 240 minutes and BFR =
200 mL/min. The association of patient characteristics
with low Kt/V (<1.2) was assessed using a generalized
estimating equation (GEE) model with logit link func-
tion. The model included all variables listed in Table 1,
adjusted for study phase, and accounted for facility clus-
tering effects. The proportion of cases of low Kt/V attrib-
utable to insufficient treatment (i.e., below a certain
threshold of BFR, DFR, or TT) was obtained by estimating
the population attributable fraction (AF), i.e., the propor-
tion of cases of low Kt/V that would not have occurred if
everyone in the study population had sufficient levels (at
or above the threshold level) of these treatment param-
eters. The AF is a function of both the prevalence and
effect size of each parameter. For example, to assess the AF
of insufficient TT (TT <240 minutes), a fitted GEE model
was used, treating BFR, DFR, and TT as continuous
variables, to estimate the percentage of patients with
low Kt/V attributable to having TT <240 minutes after
counterfactually assigning all observed values under 240
minutes to exactly 240 minutes. The AF value can thus be
interpreted as the proportion of cases of low Kt/V that
could potentially be prevented by improving the treat-
ment to the threshold levels as defined in these analyses.
Attributable fraction models were adjusted for DOPPS
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phase and the following baseline covariates: age, gender,
vintage, weight, height, 13 summary comorbid conditions
(listed in Table 1), serum albumin, and creatinine.
For mortality analyses, patients were followed from
DOPPS entry until death or the earliest of the following
censoring events: 7 days after departure from the facility
for change of treatment modality, withdrawal from dialy-
sis, return of renal function, kidney transplantation, trans-
fer to another facility, or the end of follow up. Cox
regression was used to estimate the effect of low Kt/V on
all-cause mortality, adjusting for the same potential con-
founders noted above for the logistic models and stratified
by DOPPS phase. Kt/V was treated in these models as a
continuous variable and categorically as a set of indicator
variables. Interaction between Kt/V and weight and body
mass index (BMI) was assessed among both men and
women. In addition, Kt/V was also measured at the facility
level as the proportion of patients in each facility with low
Kt/V. The associations of both BFR and TT with all-cause
mortality were similarly analyzed at both the patient and
facility level. In all analyses of these facility-level predic-
tors, adjustment was also made for two other facility-level
variables in order to further account for facility-level varia-
tion in patient casemix and in practices that may not have
been captured by the patient-level adjustments: mean
baseline hemoglobin level and the proportion of patients
with baseline serum phosphorus >5.5 mg/dL. The missing
indicator method was used in model-based analyses to
include the following variables with at least 1% missing-
ness in models: albumin (11%), height (5%), and creati-
nine (1%). All statistical analyses were performed using
the SAS statistical package, version 9.2 (SAS Institute,
Cary, NC, USA).
RESULTS
Trends in Kt/V and other characteristics
across DOPPS phases
Among the 5784 patients included in the analysis, 586
patients died (10%) during a median follow up of 25.2
months (IQR: 20.9–32.0). Low Kt/V (<1.2) was observed
in 26% of patients overall. However, the median facility
percentage of patients with low Kt/V declined from 33%
in DOPPS 1 to 18% in DOPPS 4 (Figure 1). In each study
phase, large variability was seen across Japanese dialysis
facilities in the percentage of HD patients with low Kt/V
(<1.2), ranging from close to 0% to >50% of patients.
Mean (SD) Kt/V was 1.28 (0.22) in men and 1.51 (0.27)
in women, with the highest values observed in DOPPS 4
(Figure 2). The prevalence of low Kt/V declined in men
from 37% in DOPPS 1 to 27% in DOPPS 4, and it
declined in women from 15% in DOPPS 1 to 10% in
DOPPS 4. Both BFR and TT were somewhat higher on
average in men than women (Figure 3A and B). Trends in
practice across the study phases indicate higher BFRs and
shorter TTs in recent years in Japan. Dialyzate flow rate is
largely a facility-based practice and did not appear to be
customized according to patient gender; thus, the distri-
bution was similar for men and women (Figure 3C). Over
90% of facilities in each phase did not individualize DFRs,
defined as having at least 90% of patients within 50 mL/
min of the facility median DFR.
Associations with low Kt/V
Table 1 shows the means and percentages of baseline
patient characteristics among all study patients by gender
and Kt/V level. In a logistic model using GEE with all
predictors listed in Table 1, the following variables were
positively associated with low baseline Kt/V (<1.2): male
gender, diabetes, greater body weight, greater height,
shorter vintage on dialysis, neurologic disease, lower
albumin, shorter dialysis TT, lower BFRs or DFRs
(Table S1). Testing effect modification by gender for each
of these associations revealed that the associations
between weight and height with low Kt/V were stronger
among men than women (P for each interaction < 0.05).
A descriptive analysis revealed a consistent pattern of
higher observed mean Kt/V levels for female vs. male
patients across the entire range of observed patient body
weights among 1735 patients with a TT of 240 minutes
and a BFR of 200 mL/min (Figure 4). Despite variation in
Kt/V by gender at the same weight, we did not find evi-
dence that the relationship between Kt/V and mortality
differed by weight or BMI in either men or women (P for
interactions > 0.05).
Figure 1 Distribution of facilities according to the propor-
tion of their patients with low Kt/V (<1.2) by DOPPS phase.
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The results in Table 2 indicate that the odds of a patient
having Kt/V < 1.2 was 8.1 times greater (95% CI: 6.1–
10.7) when dialyzing <240 minutes. The odds ratios
(ORs) of having low Kt/V for patients with a BFR of
<200 mL/min and DFR of <500 mL/min were 2.9 (95%
CI: 2.3–3.6) and 1.8 (95% CI: 1.3–2.4), respectively. We
then estimated the proportion of low Kt/V cases attribut-
able to a TT <240 minutes, BFR <200 mL/min, and DFR
<500 mL/min. While shorter TT was a stronger predictor
of low Kt/V than low BFR, the higher prevalence of low
BFR in the study sample (35% vs. 13% with TT <240
minutes) resulted in a higher proportion of cases of low
Figure 2 Patient single pool Kt/V categories by gender and DOPPS phase.
Table 2 Proportion of Kt/V cases <1.2 attributable to treatment practices below a specified cut point in Japan for: (a) all
study patients, (b) male patients, and (c) female patients
Subgroup (N Kt/V < 1.2/N patients)
Prevalence of
parameter (%)
OR (95% CI) of
Kt/V < 1.2
Attributable
fraction (%)
(a) All patients (n = 1189/4376)
TT < 240 min 13 8.1 (6.1,10.7) 13
BFR < 200 mL/min 35 2.9 (2.3,3.6) 15
DFR < 500 mL/min 19 1.8 (1.3,2.4) 3
Any combinationa 54 (any) — 30
(b) Male (n = 964/2657)
TT < 240 min 11 9.8 (6.9,13.9) 10
BFR < 200 mL/min 26 2.9 (2.3,3.7) 10
DFR < 500 mL/min 19 2.3 (1.6,3.2) 3
Any combinationa 47 (any) — 24
(c) Female (n = 225/1719)
TT < 240 min 16 7.6 (5.2,11.2) 22
BFR < 200 mL/min 48 3.7 (2.4,5.7) 43
DFR < 500 mL/min 19 1.2 (0.7,2.0) 2
Any combinationa 65 (any) — 61
Three separate GEE models, overall and by gender, which simultaneously adjust for all three treatment practices.
All models additionally adjusted for study phase, age, gender (model (a) only), vintage, height, weight, 13 summary comorbidities, serum
albumin, and serum creatinine, and accounted for facility clustering effects. Analyses restricted to DOPPS phases 1–3 due to unavailability of
DFR data in DOPPS 4.
aPrevalence for any combination is the proportion of patients with any one of the three values below the cut point; attributable fraction for
this row is calculated if all values (1, 2, or 3) below the cut point were increased to the cut point.
BFR = blood flow rate; DFR = dialyzate flow rate; TT = treatment time; — = not applicable.
Kimata et al.
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Figure 3 (A) Patient blood flow rate (BFR) categories by gender and DOPPS phase. (B) Patient treatment time (TT) categories
by gender and DOPPS phase. Over 90% of patients had TT at exactly 180, 210, 240, 270, or 300 min. All remaining values
were rounded to the nearest 30-min interval. (C) Patient dialyzate flow rate (DFR) categories by gender and DOPPS phase.
Dialyzate flow rate data unavailable in DOPPS 4.
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Kt/V being attributed to BFR <200 mL/min (15%) than a
short TT (13%). Low DFR had a weaker association with
low Kt/V, but still provided additional predictive power
even after accounting for TT and BFR. The AF calculated
for all three practices combined was 30%. The analysis
was repeated for each gender and results are shown in
Table 2. A Kt/V cut point of 1.6 was also analyzed for
women and showed an AF of 21% for all three practices
combined. In a sensitivity analysis using a different cut
point for BFR, 72% of men and 91% of women had BFR
<220 mL/min (79% overall). The proportion of cases of
low Kt/V attributable to BFR <220 mL/min was 29% in
men and 69% in women (37% overall).
Kt/V and mortality
The relation between patient-level Kt/V and all-cause mor-
tality was analyzed in the total sample and by gender
(Table 3). In a fully adjusted model treating Kt/V as a
continuous variable, lower Kt/V was associated with mor-
tality (hazard ratio [HR] per 0.1 lower Kt/V = 1.10; 95%
CI: 1.05–1.14). This association was stronger among
women (HR = 1.13; 95% CI: 1.07–1.20) than men
(HR = 1.06; 95% CI: 1.00–1.12) (P for the interaction
between Kt/V and gender = 0.05). The results are qualita-
tively similar when Kt/V was treated as three binary pre-
dictors in the models (Table 3). The HR, comparing
Kt/V ≥ 1.6 to Kt/V < 1.2, was 0.36 for women (95% CI:
0.23–0.56) and 0.68 for men (95% CI: 0.45–1.04).
Facility-level models provided further evidence of
greater patient mortality with greater exposure to low
Kt/V. In a model including both patient and facility-level
adjustments (Table 4, model 5), facilities with a larger
percentage of patients with low Kt/V displayed higher
mortality (HR per 20% patients with low Kt/V = 1.14;
95% CI: 1.00–1.31). Categorical analyses indicated a
positive dose–response association between the propor-
tion of facility patients with low Kt/V and mortality
(Table 4).
Mortality: relationship with BFR and TT
Because low Kt/V was strongly associated with mortality
and substantial proportions of low Kt/V cases observed in
Japan were attributable to having a low BFR (<200 mL/
min) or low TT (<240 minutes), we estimated the effects
of BFR and TT on all-cause mortality. The results indicate
a clear inverse association between prescribed BFR and
mortality (Figure S1). This inverse relation was also
observed as a facility practice, with HR = 1.46 (95% CI:
1.04–2.03) for patients treated in facilities with a mean
prescribed BFR <180 mL/min compared with the refer-
ence group of 180–210 mL/min. Treatment time at both
Figure 4 Mean Kt/V, by gender and weight, for n = 1735
patients with treatment time (TT) of 240 min and prescribed
blood flow rate of 200 mL/min. Mean values hidden for
subgroups with less than 30 patients.
Table 3 Patient-level Kt/V and all-cause mortality, overall and by gender
All patients Male Female
N patients 5784 3530 2254
N deaths (%) 586 (10) 369 (10) 217 (10)
Continuous Kt/V
Per 0.1 lower Kt/V 1.10 (1.05–1.14) 1.06 (1.00–1.12) 1.13 (1.07–1.20)
Categorical Kt/V
<1.2 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
1.2–1.4 0.73 (0.60–0.89) 0.79 (0.61–1.03) 0.58 (0.38–0.88)
1.4–1.6 0.75 (0.59–0.96) 0.85 (0.62–1.16) 0.64 (0.45–0.91)
≥1.6 0.48 (0.34–0.67) 0.68 (0.45–1.04) 0.36 (0.23–0.56)
Note: Hazard ratios (95% CI) shown; P values for interaction between gender and Kt/V were 0.05 (continuous) and 0.15 (categorical). Separate
Cox models adjusted for age, sex, vintage, weight, height, 13 summary comorbidities, serum albumin, and creatinine, stratified by DOPPS
phase, and accounting for facility clustering. Results of an additional analysis of patients with Kt/V < 1.2 vs. Kt/V ≥ 1.2 were HR = 1.44
(1.19–1.75) for all patients, HR = 1.26 (0.98–1.61) for men, and HR = 1.92 (1.39–2.64) for women.
Kimata et al.
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the patient and facility level was also inversely associated
with mortality (Figure S2). Mortality rates were higher for
patients with TT of 180 minutes (HR = 1.54, 95% CI:
1.16–2.04) than for patients in the reference group
(TT = 240 minutes), and in patients treated in facilities
with the lowest mean TT (HR = 1.17 for facility mean TT
<230 minutes compared to reference group of 230–250
minutes, 95% CI: 0.90–1.50).
DISCUSSION
Hemodialysis in Japan is distinguished from that of most
non-Asian countries in a multitude of ways including
much lower mortality rates, smaller patient body size,
lower BFRs used for HD, and much lower use of catheters
for vascular access. In view of these many differences and
others, we undertook the current investigation to under-
stand which factors are related to Kt/V achievement in
Japan, as well as to understand the relationship of Kt/V to
survival. The DOPPS shows that the percentage of patients
with “low Kt/V” (<1.2) is still substantial in some coun-
tries, including Japan at 18% which is among the highest
in the DOPPS countries.10 In 1997, Shinzato et al.14 pub-
lished compelling findings from the Japanese Society for
Dialysis Therapy (JSDT), showing that the odds of a
patient dying in the year of study (1994) was sharply
higher for patients having a Kt/V < 1.2 in the prior year
among a large cohort (n = 53,867) of HD patients in
Japan. These findings along with those from numerous
other studies have led various HD practice guideline com-
mittees in many countries to recommend that HD patients
receive sufficient dialysis to achieve, at minimum, an
spKt/V of 1.2 or higher for thrice weekly HD.15 In this
study, we expand on the findings of Shinzato et al. by
showing higher mortality risk in Japan for HD patients
with an spKt/V < 1.2. Despite practice guidelines and
extensive ongoing evidence of poorer survival for patients
with Kt/V < 1.2, a substantial fraction of Japanese HD
patients still receive dialysis doses below the guideline
recommendation. Across Japanese dialysis units in DOPPS
4 (2009–2011), half of all facilities had >18% of their
patients with low Kt/V (<1.2) and one-fourth of all facili-
ties had >28% of their patients with low Kt/V. These
results represent a large improvement in dialysis dose
achievement in Japan since DOPPS 1 (1999–2001), but
these percentages have been higher than reported for
other DOPPS countries.10,16,17 Thus, even though Japan
exhibits one of the lowest mortality rates in the world for
HD patients, opportunities remain for further improve-
ments, such as a higher dialysis dose for HD patients
currently receiving doses below the current JSDT and
KDOQI guideline recommendations of spKt/V 1.2 or
higher.
In examining patient characteristics associated with low
Kt/V, a strong relationship was seen between low Kt/V and
male gender and larger body size, as has been shown in
prior studies.18,19 Among the large fraction of male HD
patients in Japan having a low Kt/V, mortality rates were
26% higher compared with patients having a Kt/V ≥ 1.2.
Higher body weight had a stronger association with low
Kt/V among male than female patients which may indicate
the need for greater attention to providing a higher Kt/V
for patients of larger body size, especially among male HD
patients in Japan. Previously, the HEMO trial investiga-
tors18,20,21 showed longer survival (HR = 0.81, P = 0.02)
for female HD patients randomized to the higher (spKt/V
1.7 ± 0.1) vs. standard (spKt/V 1.3 ± 0.1) dose group in a
subgroup analysis of the HEMO trial. In contrast, little
Table 4 Facility-level Kt/V and all-cause mortality by level of adjustment
Model 1 Model 2 Model 3 Model 4 Model 5
Unadjusted + Demographicsa +13 Comorbidities
+ Albumin
and creatinine
+ Facility-level
adjustmentsb
Continuous Kt/V: % of patients with low Kt/V (<1.2)
Per 20% more patients 1.10 (0.98–1.23) 1.15 (1.02–1.28) 1.12 (0.99–1.26) 1.15 (1.02–1.30) 1.14 (1.00–1.31)
Categorical Kt/V: % of patients with low Kt/V (<1.2)
0% to 12% 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
12% to 23% 1.13 (0.85–1.52) 1.14 (0.88–1.46) 1.19 (0.91–1.54) 1.20 (0.93–1.56) 1.18 (0.91–1.53)
23% to 36% 1.16 (0.86–1.56) 1.22 (0.93–1.61) 1.26 (0.94–1.68) 1.28 (0.96–1.71) 1.22 (0.92–1.62)
≥36% 1.27 (0.91–1.76) 1.37 (1.00–1.87) 1.29 (0.94–1.76) 1.34 (0.98–1.84) 1.37 (1.00–1.88)
Note: Hazard ratios (95% CI) shown; n = 5784 patients from DOPPS phases 1–4. All Cox models stratified by DOPPS phase and accounting
for facility clustering.
aDemographics: gender, age, vintage, weight, height.
bFacility-level adjustments: facility mean hemoglobin and facility % of patients with serum phosphorus > 5.5 mg/dL.
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difference was seen in mortality rates between male HD
patients randomized to the higher vs. standard dose group
arms of the HEMO trial. Subsequently, Port et al.22 con-
firmed these findings in the non-trial setting in describing
a strong association between higher dose and lower mor-
tality rates in women but not in men, using the average
urea reduction ratio (URR) of incident HD patients in the
United States and eKt/V of HD patients on HD for at least
1 year across seven DOPPS countries. In the present study,
we have seen low Kt/V among 15% of female HD patients
in Japan in DOPPS 1, which had declined to 10% in
DOPPS 4. Similar to the prior non-Japanese findings of
the HEMO trial and Port et al., in Japan we now describe
a stronger association between spKt/V and mortality
among female than male HD patients. Our findings
suggest a mortality benefit for women on HD in Japan
extending to spKt/V levels at least as high as spKt/V 1.6. In
addition, we demonstrate that spKt/V achievement for
female HD patients is higher than for male HD patients of
the same body weight, TT, and BFR, which suggests that
the dialyzable fluid volume differs between female and
male HD patients at any given body weight. A possible
explanation for this surprising mortality risk finding
by gender was suggested based on a national US study by
Ramirez et al.23 This study confirmed these differences by
gender; however, it showed that when dialysis dose was
normalized to body surface area (SAN-stdKt/V) rather
than to body fluid volume (in Kt/V), the functional form
of the association was similar in shape for men and
women, and survival continued to improve as surface area
normalized dialysis dose (SAN-stdKt/V) increased in both
men and women. Thus, they suggest that SAN-stdKt/V
may be a better indicator for HD adequacy than when
dose was normalized to body fluid volume as eKt/V or
stdKt/V.23 From our results, in combination with those
from prior studies, a consistent pattern of evidence has
been observed for longer survival of female HD patients at
higher Kt/V levels. Guideline committees and quality
improvement initiatives should take advantage of this
knowledge to improve outcomes of HD patients, espe-
cially women. The association of higher Kt/V with longer
survival in female HD patients is one consideration incor-
porated within the United Kingdom Renal Association’s
recommendation for dialysis dose achievement in HD
patients.24
Since Kt/V is still used as the standard indicator of
dialysis dose, the current study is useful in revealing
several readily modifiable HD practices that were strongly
and independently related to low delivered Kt/V in Japan.
These practices included having a BFR <200 mL/min, a
TT <240 minutes, and a DFR <500 mL/min. We estimated
that 30% of patients with low Kt/V were attributable to
combinations of these three practices—61% for women
and 24% for men. Among these three practices, low Kt/V
was more strongly associated with TT <240 minutes
(OR = 8.1) than either BFR <200 mL/min (OR = 2.9) or
DFR <500 mL/min (OR = 1.8). However, slightly more
cases of low Kt/V could be prevented by improving BFR
rather than TT to the threshold levels assumed in these
analyses, because a greater proportion of the HD popula-
tion has a “low” value for BFR. Providing patients with a
DFR <500 mL/min contributed less (3% of low Kt/V
cases). Among women, an estimated 43% of low Kt/V
cases were attributable to BFR <200 mL/min (10% for
men). An even higher fraction of low Kt/V cases were
attributed to a low BFR when a higher contrast level of
220 mL/min was used: 69% of female cases and 29% of
male cases. In addition to BFR, the practice of providing
patients with a TT <240 minutes also contributed sub-
stantially to low Kt/V in this patient population (13% of
low Kt/V cases). Thus, these results indicate three easily
modifiable approaches for improving Kt/V achievement in
Japanese HD patients. Blood flow rates in Japan are sub-
stantially lower than those in the 11 other countries in
DOPPS 4 with a BFR ≤220 mL/min prescribed for 80% of
patients. A lower BFR may allow more frequent use of AVF
with longer AVF patency in Japan compared with other
countries.25 However, despite this possibility, our mortal-
ity analyses indicate that, overall, a slightly higher BFR
either at the patient level or as a facility practice in Japan
is associated with a substantially lower mortality rate. In
addition, similar to prior international DOPPS findings
and prior JSDT findings of longer HD patient survival
with longer patient dialysis TT,9,14,16 the current study
provides additional evidence of longer patient survival in
facilities with longer average TT.
The findings from the present work are subject to meth-
odological limitations. Because the study is observational,
we cannot rule out confounding by unmeasured risk
factors for each outcome. To deal with such bias, we
adjusted for several potential confounders. We also
restricted the analysis to patients receiving HD three times
per week who had been on dialysis for more than 1 year
to reduce potential influence of residual renal function.
Additionally, we tried to minimize unmeasured confound-
ers by examining the practices under consideration as
both patient-level and facility-level predictors of mortality,
finding qualitatively consistent associations with mortal-
ity. In practice-based analyses, we also adjusted for a
potential role of other practices related to achieving
levels of phosphorus and anemia control. Nevertheless,
effect estimates could have been biased due to other
Kimata et al.
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unmeasured or incompletely specified patient-level or
facility-level factors.
Lastly, these findings in Japan may be relevant to other
countries with a relatively high prevalence of spKt/V of
<1.2. In the United States, BFR is typically high and Kt/V
values >1.2 are readily achieved in most patients, despite
short average TT. Along with the introduction of the
Quality Incentive Program payment reducing composite
rate payment for URR <65% in 2012, the percentage of
patients is now only 5% as of August 2012.26 Compared to
the United States, the prevalence of spKt/V < 1.2 is higher,
and average BFR lower, in all other DOPPS countries.10 In
addition to Japan, DOPPS countries with high prevalence
of Kt/V < 1.2 include Italy (26%) and China (28%).27
Prevalence of URR <65% was the second highest in
Japan (32%) among DOPPS countries, only lower than
Saudi Arabia (48%) (Karkar et al. ASN 2012 abstract,
TH-PO802; page 284A).
In conclusion, we have provided a detailed investiga-
tion of the trends in low Kt/V, the association of low Kt/V
with survival by gender, and its relation with modifiable
HD practices in the Japanese DOPPS patient population
from 1999 to 2011. The results of this investigation
suggest that small changes in modifiable practices, specifi-
cally increasing BFRs and dialysis session TTs for some
patients, may decrease the percentage of patients with low
Kt/V and likely enhance the survival of these patients.
These findings from Japan may apply to other countries
where large fractions of HD patients have Kt/V levels less
than 1.2.
ACKNOWLEDGMENTS
The DOPPS program is supported by Amgen, Kyowa
Hakko Kirin, AbbVie Inc., Sanofi Renal, Baxter Health-
care, Vifor Fresenius Medical Care Renal Pharma, Ltd, and
Fresenius Medical Care. Additional support for specific
projects and countries is also provided in Canada by
Amgen, BHC Medical, Janssen, Takeda, Kidney Founda-
tion of Canada (for logistics support); in Germany by
Hexal, DGfN, Shire, WiNe Institute; for PDOPPS in Japan
by the Japanese Society for Peritoneal Dialysis (JSPD). All
support is provided without restrictions on publications.
DISCLOSURE STATEMENT
Dr Robinson has received speaker fees for Kyowa Hakko
Kirin. Dr Pisoni has received speaker fees from Amgen,
Kyowa Hakko Kirin, and Vifor; has served as a consultant
for Pursuit Vascular; and has served on an advisory panel
for Merck.
Manuscript received September 2013; revised December
2013.
REFERENCES
1 Nakai S, Iseki K, Itami N, et al. An overview of regular
dialysis treatment in Japan (as of 31 December 2010).
Ther Apher Dial. 2012; 16:483–521.
2 U.S. Renal Data System. USRDS 2010 Annual Data Report:
Atlas of Chronic Kidney Disease and End-Stage Renal Disease
in the United States. Bethesda, MD, National Institutes of
Health, National Institute of Diabetes and Digestive and
Kidney Diseases. 2010.
3 2012 CORR Report—Treatment of End-Stage Organ
Failure in Canada, 2001 to 2010: Canadian Institute for
Health Information, 2012. Available from: https://
secure.cihi.ca/estore/productFamily.htm?locale=en&pf
=PFC1696 (accessed date: December 11, 2012).
4 The Renal Association UK Renal Registry. The Fourteenth
Annual Report December 2011, 2011. Available from:
http://www.renalreg.com/Reports/2011.html (accessed
date: January 13, 2013).
5 ANZDATA Registry. Thirty Fourth Annual Report 2011
Australia and New Zealand Dialysis and Transplant
Registry. Adelaide, SA. In: Clayton P, Hurst K, ed,
2011. Available from: http://www.anzdata.org.au/v1/
report_2011.html (accessed date: February 1, 2013).
6 Goodkin DA, Bragg-Gresham JL, Koenig KG, et al.
Association of comorbid conditions and mortality in
hemodialysis patients in Europe, Japan, and the United
States: The Dialysis Outcomes and Practice Patterns
Study (DOPPS). J Am Soc Nephrol. 2003; 14:3270–3277.
7 Goodkin DA, Pisoni RL, Locatelli F, et al. Hemodialysis
vascular access training and practices are key to improved
access outcomes. Am J Kidney Dis. 2010; 56:1032–
1042.
8 Pisoni RL, Arrington CJ, Albert JM, et al. Facility hemo-
dialysis vascular access use and mortality in countries
participating in DOPPS: An instrumental variable analy-
sis. Am J Kidney Dis. 2009; 53:475–491.
9 Tentori F, Zhang J, Li Y, et al. Longer dialysis session
length is associated with better intermediate outcomes
and survival among patients on in-center three times per
week hemodialysis: Results from the Dialysis Outcomes
and Practice Patterns Study (DOPPS). Nephrol Dial Trans-
plant. 2012; 27:4180–4188.
10 2010 Annual Report of the Dialysis Outcomes and Practice
Patterns Study: Hemodialysis Data 1999–2008. Ann Arbor,
MI, Arbor Research Collaborative for Health. 2010. Avail-
able from: http://www.dopps.org/annualreport/ (accessed
date: January 29, 2014).
11 Pisoni RL, Gillespie BW, Dickinson DM, et al. The Dialy-
sis Outcomes and Practice Patterns Study (DOPPS):
Design, data elements, and methodology. Am J Kidney
Dis. 2004; 44:7–15.
Gender, low Kt/V, and mortality in Japanese HD patients
Hemodialysis International 2014; 18:596–606 605
12 Young EW, Goodkin DA, Mapes DL, et al. The Dialysis
Outcomes and Practice Patterns Study (DOPPS):
An international hemodialysis study. Kidney Int. 2000;
57:S74–S81.
13 Daugirdas JT. Second generation logarithmic estimates of
single-pool variable volume Kt/V: An analysis of error.
J Am Soc Nephrol. 1993; 4:1205–1213.
14 Shinzato T, Nakai S, Akiba T, et al. Survival in long-term
haemodialysis patients: Results from the annual survey of
the Japanese Society for Dialysis Therapy. Nephrol Dial
Transplant. 1997; 12:884–888.
15 KDOQI clinical practice guidelines for hemodialysis
adequacy, update 2006. 2006. Available from: http://
www.kidney.org/Professionals/kdoqi/guideline_upHD
_PD_VA/index.htm (accessed date: March 10, 2013).
16 Saran R, Bragg-Gresham JL, Levin NW, et al. Longer
treatment time and slower ultrafiltration in hemodialysis:
Associations with reduced mortality in the DOPPS.
Kidney Int. 2006; 69:1222–1228.
17 Port FK, Pisoni RL, Bommer J, et al. Improving outcomes
for dialysis patients in the international Dialysis Out-
comes and Practice Patterns Study. Clin J Am Soc Nephrol.
2006; 1:246–255.
18 Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis
dose and membrane flux in maintenance hemodialysis.
N Engl J Med. 2002; 347:2010–2019.
19 Wolfe RA, Ashby VB, Daugirdas JT, et al. Body size, dose
of hemodialysis, and mortality. Am J Kidney Dis. 2000;
35:80–88.
20 Rocco MV, Dwyer JT, Larive B, et al. The effect of dialysis
dose and membrane flux on nutritional parameters in
hemodialysis patients: Results of the HEMO Study.
Kidney Int. 2004; 65:2321–2334.
21 Depner T, Daugirdas J, Allon M, et al. Dialysis dose and
the effect of gender and body size on outcome in the
HEMO Study. Kidney Int. 2004; 65:1386–1394.
22 Port FK, Wolfe RA, Hulbert-Shearon TE, et al. High
dialysis dose is associated with lower mortality among
women but not among men. Am J Kidney Dis. 2004;
43:1014–1023.
23 Ramirez SP, Kapke A, Port FK, et al. Dialysis dose scaled to
body surface area and size-adjusted, sex-specific patient
mortality. Clin J Am Soc Nephrol. 2012; 7:1977–1987.
24 Mactier R, Hoenich N, Breen C. The renal association
clinical guidelines; haemodialysis guidelines 5.1 to 5.10.
Final draft. The renal association clinical guidelines, 2009.
Available from: http://www.renal.org/Clinical/Guidelines
Section/Haemodialysis.aspx#s5 (accessed date: March 23,
2013).
25 Asano M, Thumma J, Oguchi K, et al.; J-DOPPS Research
Group. Vascular access care and treatment practices
associated with outcomes of arteriovenous fistula: Inter-
national comparisons from the Dialysis Outcomes and
Practice Patterns Study. Nephron Clin Pract. 2013;
124:23–30.
26 Dialysis Outcomes and Practice Patterns Study Practice
Monitor website. Available from: http://www.DOPPS.org/
DPM (accessed date: March 10, 2013).
27 Wang M, Bieber BA, Guidinger M, et al. Dialysis treat-
ment time, dialysis frequency, and delivered single pool
Kt/V among hemodialysis patients in the China Dialysis
Outcomes and Practice Patterns Study (DOPPS). FP624.
Nephrol Dial Transplant Plus. 2012; 27(Suppl 2):ii280.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the
online version of this article at the publisher’s web-site:
Figure S1 Patient-level and facility-level blood flow rate
and all-cause mortality; Cox models stratified by DOPPS
phase and adjusted for age, gender, vintage, weight,
height, 13 summary comorbid conditions, serum
albumin, and creatinine, and accounting for facility clus-
tering effects. Results were consistent after additional
adjustment for treatment time (TT). Facility-level model
additionally adjusted for two facility-level parameters:
facility mean hemoglobin and facility % of patients with
serum phosphorus > 5.5 mg/dL. P value when treating
blood flow rate as a continuous variable was 0.28 for
patient level and 0.58 for facility mean blood flow rate.
Figure S2 Patient and facility-level treatment time
(TT) and all-cause mortality; Cox models stratified by
DOPPS phase and adjusted for age, gender, vintage,
weight, height, 13 summary comorbid conditions, serum
albumin, and creatinine, and accounting for facility clus-
tering effects. Results were consistent after additional
adjustment for blood flow rate. Facility-level model addi-
tionally adjusted for two facility-level parameters: facility
mean hemoglobin and facility % of patients with serum
phosphorus > 5.5 mg/dL. Over 90% of patients had treat-
ment time at exactly 180, 210, 240, 270, or 300 min. All
remaining values were rounded to the nearest 30-min
interval for the patient-level analysis. P value when treat-
ing TT as a continuous variable was 0.005 for patient level
and 0.02 for facility mean TT.
Table S1 Adjusted odds ratio (95% CI) of Kt/V < 1.2 for
patient characteristics, overall and by gender.
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